Speaker

Rick Wiese, Ph.D.
Head of Singleplex & Special Protein Platforms R&D
Merck KGaA, Darmstadt, Germany
Ultrasensitive assay technologies have enabled the measurement of low-abundant blood-based biomarkers of neurodegenerative diseases. They reduce the need for invasive CSF sample collection, streamline sample acquisition and screening, and empower the study of the transitions from health to disease.
Neurofilament light chain (NF-L) is a valuable biomarker for assessing the progression and treatment of Alzheimer’s Disease, Multiple Sclerosis, and Huntington’s Disease and is under investigation as a potential biomarker for several other neurological disorders.
Join this webinar to learn how ultrasensitive Single Molecule Counting (SMC®️) technology enables measurements of a low-abundant blood-based neurodegeneration biomarker.
You’ll discover how the assay helps researchers investigate neurodegenerative conditions and neurological injury with consistent and reliable measurement of NF-L at sub-pg/mL concentrations in human blood and CSF samples.
In this webinar, you will learn about:
- Why NF-L is emerging as a critical blood-based neurodegenerative biomarker;
- The challenges with measuring low-abundant biomarkers;
- How SMC®️ technology was used to develop assays for easy and sensitive detection of low-abundant blood-based biomarkers.
For Research Use Only. Not For Use In Diagnostic Procedures.
Webinar brought to you by:
Enter your details to view this webinar on-demand
[Merck] Webinar 24-May-22 Developing a Novel Ultrasensitive
All Bitesize Bio emails contain an unsubscribe link.
You can review our privacy policy, cookie policy and terms and conditions online.